Neil Clark of Destiny Pharma discusses positive update from FDA on their XF-73 nasal gel

Neil Clark, CEO of Destiny Pharma #DEST explains the positive update from US FDA, on their XF-73 nasal gel, that will enable simplification of the Phase 3 study design, which is expected to shorten the overall clinical development programme in the U.S.

The key points from the FDA's feedback are:

·    The FDA agreed to the proposed Phase 3 design comparing XF-73 Nasal gel to placebo on top of standard of care for the prevention of post-surgical staphylococcal infections following certain breast surgery operations. This type of surgery is being proposed as patients can experience a relatively high infection rate following the current standard of care and there is a clear unmet medical need.

·    The FDA is open to the collection of microbiological data during the proposed Phase 3 study that could lead to the development of a surrogate marker for clinical efficacy in other types of surgery.

·  Based on the favourable safety profile from the clinical development programme so far, the FDA has confirmed that no specialised nasal examinations are needed in the Phase 3 study. In line with the above, the FDA has also removed the previous requirement to clinically evaluate skin sensitisation.

·    The regulatory feedback will enable Destiny Pharma to simplify the Phase 3 study design and is expected to shorten the overall clinical development programme in the US.

To read full the RNS click here